Five Prime Therapeutics (NASDAQ:FPRX) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.
Several other research firms have also recently commented on FPRX. Wells Fargo & Co lowered their price target on shares of Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating for the company in a report on Thursday, August 9th. Wedbush boosted their price target on shares of Five Prime Therapeutics from $17.00 to $19.00 and gave the stock a “hold” rating in a report on Friday, August 10th. Leerink Swann assumed coverage on shares of Five Prime Therapeutics in a report on Thursday, September 13th. They set an “outperform” rating and a $24.00 price target for the company. BidaskClub upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, October 19th. Finally, Citigroup lowered their price target on shares of Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating for the company in a report on Monday, August 20th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $29.67.
NASDAQ FPRX traded up $0.43 on Monday, hitting $12.47. 214,446 shares of the stock were exchanged, compared to its average volume of 413,808. Five Prime Therapeutics has a fifty-two week low of $10.35 and a fifty-two week high of $27.00. The stock has a market capitalization of $427.01 million, a PE ratio of -2.32 and a beta of 3.23.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). Five Prime Therapeutics had a negative return on equity of 41.52% and a negative net margin of 221.67%. The firm had revenue of $5.77 million for the quarter, compared to analyst estimates of $7.45 million. Sell-side analysts predict that Five Prime Therapeutics will post -4.32 earnings per share for the current year.
Several large investors have recently modified their holdings of FPRX. Price Capital Management Inc. purchased a new stake in shares of Five Prime Therapeutics during the 3rd quarter worth approximately $118,000. Xact Kapitalforvaltning AB purchased a new stake in Five Prime Therapeutics in the 3rd quarter valued at $145,000. Dynamic Technology Lab Private Ltd purchased a new stake in Five Prime Therapeutics in the 3rd quarter valued at $190,000. Jefferies Group LLC purchased a new stake in Five Prime Therapeutics in the 3rd quarter valued at $191,000. Finally, BlueMountain Capital Management LLC raised its position in Five Prime Therapeutics by 398.9% in the 3rd quarter. BlueMountain Capital Management LLC now owns 14,766 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 11,806 shares during the last quarter. Institutional investors and hedge funds own 77.08% of the company’s stock.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.